Cord Blood Test Might Help Predict Fatal Lung Disease in Preemies
Findings published in the Journal of Pediatrics describe growth factors in cord blood that may identify premature infants at risk for bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) – an often fatal lung disease in which the vessels carrying blood from the heart to the lungs become narrowed and dysfunctional. Identifying these babies at birth would allow earlier interventions to prevent the disease that manifests in some pre…
Research Corner: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
In this issue of Research Corner, we will address questions regarding chronic thromboembolic pulmonary hypertension (CTEPH), which is classified as Group IV pulmonary hypertension.
Role of Stem Cells in Chronic Lung Diseases Revealed
A novel population of lung stem cells plays an important role in regulating the pulmonary microvasculature — the network of tiny blood vessels where oxygen and carbon dioxide exchange takes place.
Special Stem Cells May Participate in Pulmonary Hypertension Lung Repair, Study Reports
A small group of stem cells may help repair the lungs of those with pulmonary hypertension (PH), chronic obstructive pulmonary disease (COPD), and other lung conditions, according to a study.
Reducing heart failure in pulmonary hypertension
An article published in Experimental Biology and Medicine (Volume 242, Issue 5, March, 2017) identifies a new signaling pathway that promotes heart failure in pulmonary hypertension. The study, led by Dr. Matthias Brock, from the Division of Pulmonology, University Hospital of Zurich, University of Zurich in Switzerland, reports that inhibition of MALAT1, a long noncoding RNA, reduces heart hypertrophy in mice with pulmonary hypertension.
Actelion obtains “Epoprostenol Act” label extension for pediatric PAH patients in Japan
Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted a label extension for dosage and administration for "Epoprostenol ACT" (0.5 mg and 1.5 mg) for the treatment of pediatric patients with pulmonary arterial hypertension (PAH).
Pulmonary Arterial Hypertension and Genetics: Interview With the Experts
In recent years, treatment advances have improved the survival rates of individuals with pulmonary arterial hypertension (PAH), a rare but devastating disease that affects an estimated 10 to 52 people per million.1,2 In addition, developments in genetics and genomics technology have begun to illuminate the mechanisms underlying the pathogenesis of PAH.
Blocking Factor in Lungs Could Be Way to Treat Clotting Form of Pulmonary Hypertension
The discovery of a molecular factor that triggers blood clots in lung arteries may explain why chronic thromboembolic pulmonary hypertension (CTEPH) often occurs in patients without traditional clotting risk factors, according to a study.
Rare Disease Day 2018: #ShowYourRare
The theme for 2018 is research. Rare Disease Day 2018 is an opportunity for participants to be part of a global call on policy makers, researchers, companies and healthcare professionals to increasingly and more effectively involve patients in rare disease research.
IV-delivered Stem Cells Show Potential as Pulmonary Hypertension Therapy, Rat Study Shows
IV delivery of stem cells to rats with pulmonary arterial hypertension (PAH) reduced the animals’ harmful lung blood vessel remodeling and improved their blood flow, a study reports. Researchers said the implication was that the stem cells could be used as a treatment for PAH. They used a type of stem cell known as an mesenchymal stromal cell, or MSC, in their study.
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter